PUBLISHER: TechSci Research | PRODUCT CODE: 1262027
PUBLISHER: TechSci Research | PRODUCT CODE: 1262027
Menopausal Hot Flashes Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Type, By Treatment Type, By Distribution Channel, By Region and Competition
We offer 8 hour analyst time for an additional research. Please contact us for the details.
Global Menopausal Hot Flashes Treatment market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the increasing technological advancements in products with alternative administration modes. Similarly, a rapid increase in clinical trials by healthcare companies in non-hormonal products is further expected to boost market growth during the forecast period. Moreover, a rapid increase in the number of elderly women across the globe is expected to increase menopausal hot flashes symptoms. This, in turn, is expected to create significant growth over the years. Moreover, increasing awareness about women's health on the back of public as well as private initiatives may fuel the growth of the market over the years. According to the study "Frequent hot flashes in women, 40 to 65 years of age with metabolic syndrome," published in December 2020, women over the age of 40 are more likely to have a fever, about 55.83%, and appear to be associated with metabolic syndrome. Growing focus on research and development of hot flashes is also driving the growth of the market.
Growing Incidences of Menopausal Hot Flashes
The growing incidence of menopausal hot flashes due to the consumption of alcohol, smoking, and junk foods is further boosting the market growth during the forecast period. Also, growing approval for new treatments, along with growing awareness about new menopausal hot flashes treatments, will drive the market growth over the years. Hot flashes occur in approximately 75 to 80% of menopausal women in the United States every year. It's a quick sensation of warmth that basically affects the chest, neck, and face and is also some of the main factors which are expected to drive market growth. High prevalence of fluctuating oestrogen levels and deteriorating musculoskeletal health among the women population. Moreover, new market players are investing in the development of new treatments, which will further boost the market growth during the forecast period. 73% of women in the women population have post-menopausal hot flashes due to fatigue, reduced cognitive function, sleep difficulties, and lowering their quality of life along with growing usage of medical resources, which will further demand menopausal hot flashes treatment during the forecast period. As many as 85% of perimenopausal women experience hot flashes (flushes), night sweats, and/or sleep disturbances secondary to vasomotor instability.
Growing Innovation in Medicine
Growing innovation in medicine for the treatment of menopausal hot flashes, along with major companies, is focusing on the development of new devices which will help women with menopausal hot flashes syndrome. Companies are developing a new device that reduces menopausal hot flashes. For instance, Menopod instant cooling devices, when applied to the neck, help alleviate the severity of hot flashes, and it is a portable, quick USB charging device. These smartwatch-like devices used as personal thermostats for women are further expected to boost the market growth during the forecast period. Moreover, companies are investing in the development of customizable mattresses that offer cooling and heating temperature controls which will further boost the market growth during the forecast period. There were an estimated 50 million postmenopausal women in the United States in 2010. According to Meno Martha International Menopause Directory, about 45 million of them were aged older than 52 years, the average age of natural menopause in the Western world. In 2020, the number of women aged more than 51 years was estimated to cross 50 million in the United States.
Market Segmentation
Global Menopausal Hot Flashes Treatment market can be segmented on the basis of type, treatment type, distribution channel, and by region. Based on type, the market can be further bifurcated into oral liquid and pill. Based on treatment type, the market can be further divided into hormonal treatment, non-hormonal treatment, and alternative treatment. Based on distribution channels, the market is further split into hospital pharmacies, retail pharmacies, and online pharmacies. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. On the basis of countries, the United States dominated the global Menopausal Hot Flashes Treatment market on account of the increasing number of women reaching menopausal age.
Recent Developments
- The U.S. Food and Drug Administration received a new drug application (NDA) for fezolinetant from Astellas Pharma Inc. in June 2022. (FDA). For the treatment of mild to severe vasomotor symptoms (VMS) related to menopause, the experimental oral, nonhormonal chemical fezolinetant is awaiting approval.
- In February 2021, Astellas Pharma Inc. announced the positive results from the Phase 3 pivotal SKYLIGHT 1 and SKYLIGHT 2 clinical trials of fezolinetant, which is an oral, non-hormonal compound being tested for the treatment of moderate to severe vasomotor symptoms (VMS).
- In January 2020, Bayer AG strengthened its drug discovery platform through the acquisition of Vividion Therapeutics. Vividion Therapeutics produces a variety of small molecule therapies across indications, and their initial focus was on targets relevant to oncology and immunology.
Market Players
Abbvie, Inc., Allergan PLC., Bayer AG., Cipla, Inc., Eli Lilly and Company, Emcure Pharmaceuticals Ltd., GSK PLC., Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc., Novartis Ag., Novo Nordisk AS., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and TherapeuticsMD, Inc. are some of the leading players operating in the Global Menopausal Hot Flashes Treatment Market.
Report Scope
In this report, the global Menopausal Hot Flashes Treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Menopausal Hot Flashes Treatment Market, By Type:
- Oral Liquid
- Pill
Menopausal Hot Flashes Treatment Market, By Treatment Type:
- Hormonal Treatment
- Non-Hormonal Treatment
- Alternative Treatment
Menopausal Hot Flashes Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Menopausal Hot Flashes Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Menopausal Hot Flashes Treatment Market.
Available Customizations
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Menopausal Hot Flashes Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Type (Oral Liquid v/s Pill)
- 5.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 5.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 5.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 5.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2022)
- 5.3. Product Map
6. North America Menopausal Hot Flashes Treatment Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Type (Oral Liquid v/s Pill)
- 6.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 6.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 6.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 6.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Menopausal Hot Flashes Treatment Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.2. By Treatment Type
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada Menopausal Hot Flashes Treatment Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.2. By Treatment Type
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico Menopausal Hot Flashes Treatment Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.2. By Treatment Type
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States Menopausal Hot Flashes Treatment Market Outlook
7. Europe Menopausal Hot Flashes Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Type (Oral Liquid v/s Pill)
- 7.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 7.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 7.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 7.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Menopausal Hot Flashes Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.2. By Treatment Type
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.1. Market Size & Forecast
- 7.3.2. Germany Menopausal Hot Flashes Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.2. By Treatment Type
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom Menopausal Hot Flashes Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.2. By Treatment Type
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy Menopausal Hot Flashes Treatment Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.2. By Treatment Type
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain Menopausal Hot Flashes Treatment Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Treatment Type
- 7.3.5.2.3. By Distribution Channel
- 7.3.5.1. Market Size & Forecast
- 7.3.1. France Menopausal Hot Flashes Treatment Market Outlook
8. Asia-Pacific Menopausal Hot Flashes Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Type (Oral Liquid v/s Pill)
- 8.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 8.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 8.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 8.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Menopausal Hot Flashes Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.2. By Treatment Type
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India Menopausal Hot Flashes Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.2. By Treatment Type
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan Menopausal Hot Flashes Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.2. By Treatment Type
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea Menopausal Hot Flashes Treatment Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Type
- 8.3.4.2.2. By Treatment Type
- 8.3.4.2.3. By Distribution Channel
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia Menopausal Hot Flashes Treatment Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Type
- 8.3.5.2.2. By Treatment Type
- 8.3.5.2.3. By Distribution Channel
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China Menopausal Hot Flashes Treatment Market Outlook
9. South America Menopausal Hot Flashes Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Type (Oral Liquid v/s Pill)
- 9.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 9.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 9.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 9.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Menopausal Hot Flashes Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Treatment Type
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Argentina Menopausal Hot Flashes Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Treatment Type
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.1. Market Size & Forecast
- 9.3.3. Colombia Menopausal Hot Flashes Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Treatment Type
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Brazil Menopausal Hot Flashes Treatment Market Outlook
10. Middle East and Africa Menopausal Hot Flashes Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Type (Oral Liquid v/s Pill)
- 10.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
- 10.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
- 10.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
- 10.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
- 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Menopausal Hot Flashes Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Treatment Type
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Saudi Arabia Menopausal Hot Flashes Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Treatment Type
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.1. Market Size & Forecast
- 10.3.3. UAE Menopausal Hot Flashes Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Treatment Type
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.1. Market Size & Forecast
- 10.3.1. South Africa Menopausal Hot Flashes Treatment Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Product Launches
13. Global Menopausal Hot Flashes Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. Business Overview
- 15.2. Product Offerings
- 15.3. Recent Developments
- 15.4. Financials (As Reported)
- 15.5. Key Personnel
- 15.6. SWOT Analysis
- 15.6.1 Abbvie, Inc.
- 15.6.2 Allergan PLC.
- 15.6.3 Bayer Ag.
- 15.6.4 Cipla, Inc.
- 15.6.5 Eli Lilly and Company.
- 15.6.6 Emcure Pharmaceuticals Ltd.
- 15.6.7 GSK PLC.
- 15.6.8 Glenmark Pharmaceuticals Ltd.
- 15.6.9 Hisamitsu Pharmaceutical Co. Inc.
- 15.6.10 Merck & Co. Inc.
- 15.6.11 Novartis Ag.
- 15.6.12 Novo Nordisk AS.
- 15.6.13 Pfizer, Inc.
- 15.6.14 Teva Pharmaceutical Industries Ltd.
- 15.6.15 TherapeuticsMD, Inc.
16. Strategic Recommendations
